BTMD Earnings Date: Nov 4, 2026 (Estimated) — biote Corp.
NASDAQ · Healthcare · Medical Care Facilities
Updated
When is BTMD's next earnings date?
biote Corp. (BTMD) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.05 on revenue of $44.0M.
How did BTMD do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), biote Corp. posted EPS of -$0.23 versus the $0.03 estimate, a miss of 387.5%. Revenue was $44.2M against a $46.1M estimate. The stock's 1-day post-earnings move was -27.9%.
How much does BTMD stock move after earnings?
BTMD beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 15.4% (up or down) in the day after earnings.
About biote Corp.
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.03 | -0.23 | -387.50% | $44.2M | ❌ Miss | -27.88% | -37.17% | -31.42% |
| 2026-05-06 | Q1 2026 | 0.08 | 0.06 | -25.00% | $44.9M | ❌ Miss | -5.00% | -7.73% | +6.36% |
| 2026-03-11 | Q4 2025 | 0.08 | 0.06 | -25.00% | $46.4M | ❌ Miss | -10.47% | -20.93% | -7.56% |
| 2025-11-05 | Q3 2025 | 0.09 | 0.22 | +144.44% | $48.0M | ✅ Beat | -3.07% | -9.90% | -12.97% |
| 2025-08-06 | Q2 2025 | 0.10 | 0.10 | +0.00% | $48.9M | ➖ Inline | -24.35% | -20.47% | -10.36% |
| 2025-03-12 | Q4 2024 | 0.17 | 0.10 | -41.18% | $49.8M | ❌ Miss | -25.12% | +2.93% | -18.29% |
| 2024-11-12 | Q3 2024 | 0.09 | 0.33 | +266.67% | $51.4M | ✅ Beat | +21.74% | +10.33% | +18.48% |
| 2024-05-07 | Q1 2024 | 0.03 | -0.06 | -300.00% | $46.8M | ❌ Miss | +5.20% | +3.12% | +16.64% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $56.1M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Product Revenue | 77.3% | $43.4M | -9.0% | $49.8M | $96.4M | $47.0M | $47.7M |
| Dietary Supplements | 20.2% | $11.4M | +5.7% | $10.3M | $18.3M | $9.3M | $10.7M |
| Service Revenue | 1.5% | $851K | -29.4% | $1.6M | $2.6M | $2.0M | $1.2M |
| Other Service Revenue | 0.7% | $406K | -24.1% | $702K | $1.3M | $1.3M | $535K |
| Training Service Revenue | 0.2% | $134K | -59.8% | $573K | $609K | $326K | $333K |
By region
Q2 FY26 · $44.2M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 99.5% | $44.0M | -9.5% | $50.0M | $100.6M | $48.7M | $48.6M |
| Non-US | 0.5% | $216K | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.